NCT02464111

Brief Summary

Research goals include evaluating the relative impact of maternal nutritional status versus recent dietary intake on breast milk micronutrient composition, and evaluating the impact of a maternal lipid based nutrient supplement (LNS) on breast milk micronutrient composition.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 2015

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 22, 2015

Completed
9 days until next milestone

Study Start

First participant enrolled

May 1, 2015

Completed
1 month until next milestone

First Posted

Study publicly available on registry

June 8, 2015

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2015

Completed
Last Updated

September 9, 2015

Status Verified

September 1, 2015

Enrollment Period

3 months

First QC Date

April 22, 2015

Last Update Submit

September 4, 2015

Conditions

Outcome Measures

Primary Outcomes (5)

  • Change in Cobalamin (vitamin B12) in Breast Milk

    We are observing the change in breast milk vitamin B12 over the course of 8 hours.

    Breast milk cobalamin will be assessed in an 8-hour milk sample on each of three study visit days (Visits 2, 3, and 4.) Study visits/weeks 2, 3, & 4 will each be held approximately 1 week apart.

  • Change in Pyridoxal (vitamin B6) in Breast Milk

    We are observing the change in breast milk vitamin B6 over the course of 8 hours.

    Breast milk pyridoxal will be assessed in an 8-hour milk sample on each of three study visit days (Visits 2, 3, and 4.) Study visits/weeks 2, 3, & 4 will each be held approximately 1 week apart.

  • Change in Riboflavin (vitamin B2) in Breast Milk

    We are observing the change in breast milk vitamin B2 over the course of 8 hours.

    Breast milk riboflavin will be assessed in an 8-hour milk sample on each of three study visit days (Visits 2, 3, and 4.) Study visits 2, 3, & 4 will each be held approximately 1 week apart.

  • Change in Niacin (vitamin B3) in Breast Milk

    We are observing the change in breast milk vitamin B5 over the course of 8 hours.

    Breast milk niacin will be assessed in an 8-hour milk sample on each of three study visit days (Visits 2, 3, and 4.) Study visits 2, 3, & 4 will each be held approximately 1 week apart.

  • Change in Thiamin (vitamin B1) in Breast Milk

    We are observing the change in breast milk vitamin B1 over the course of 8 hours.

    Breast milk thiamin will be assessed in an 8-hour milk sample on each of three study visit days (Visits/weeks 2, 3, and 4.) Study visits 2, 3, & 4 will each be held approximately 1 week apart.

Secondary Outcomes (6)

  • Maternal cobalamin (vitamin B12) status

    Measured once prior to first study visit (week 1)

  • Maternal pyridoxal (vitamin B6) status

    Measured once prior to first study visit (week 1)

  • Maternal riboflavin (vitamin B2) status

    Measured once prior to first study visit (week 1)

  • Maternal niacin (vitamin B3) status

    Measured once prior to first study visit (week 1)

  • Maternal thiamin (vitamin B1) status

    Measured once prior to first study visit (week 1)

  • +1 more secondary outcomes

Study Arms (6)

Group 1

EXPERIMENTAL

Treatment 1: Control - no supplement given Treatment 2: Bolus - LNS supplement provided in one dose Treatment 3: Divided Dose - LNS supplement provided in 3 doses

Other: Treatment 1: ControlDietary Supplement: Treatment 2: Bolus (LNS)Dietary Supplement: Treatment 3: Divided Dose (LNS)

Group 2

EXPERIMENTAL

Treatment 1: Control - no supplement given Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 2: Bolus - LNS supplement provided in one dose

Other: Treatment 1: ControlDietary Supplement: Treatment 2: Bolus (LNS)Dietary Supplement: Treatment 3: Divided Dose (LNS)

Group 3

EXPERIMENTAL

Treatment 2: Bolus - LNS supplement provided in one dose Treatment 1: Control - no supplement given Treatment 3: Divided Dose - LNS supplement provided in 3 doses

Other: Treatment 1: ControlDietary Supplement: Treatment 2: Bolus (LNS)Dietary Supplement: Treatment 3: Divided Dose (LNS)

Group 4

EXPERIMENTAL

Treatment 2: Bolus - LNS supplement provided in one dose Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 1: Control - no supplement given

Other: Treatment 1: ControlDietary Supplement: Treatment 2: Bolus (LNS)Dietary Supplement: Treatment 3: Divided Dose (LNS)

Group 5

EXPERIMENTAL

Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 2: Bolus - LNS supplement provided in one dose Treatment 1: Control - no supplement given

Other: Treatment 1: ControlDietary Supplement: Treatment 2: Bolus (LNS)Dietary Supplement: Treatment 3: Divided Dose (LNS)

Group 6

EXPERIMENTAL

Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 1: Control - no supplement given Treatment 2: Bolus - LNS supplement provided in one dose

Other: Treatment 1: ControlDietary Supplement: Treatment 2: Bolus (LNS)Dietary Supplement: Treatment 3: Divided Dose (LNS)

Interventions

No supplement provided.

Group 1Group 2Group 3Group 4Group 5Group 6
Treatment 2: Bolus (LNS)DIETARY_SUPPLEMENT

One LNS supplement provided in a single bolus dose in the morning

Group 1Group 2Group 3Group 4Group 5Group 6

One LNS supplement provided in 3 separate portions throughout the study visit

Group 1Group 2Group 3Group 4Group 5Group 6

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Mother 18-40 years of age
  • Apparently healthy, with no acute illness
  • Willing to stay in clinic for breast milk sampling, and adhere to all study procedures
  • months of lactation and ≥ 8 breast feeding episodes per day (usual frequency is \>20 times/day)
  • Last birth was a singleton birth
  • Only breastfeeding one child
  • Child is 4-6 months of age

You may not qualify if:

  • Current supplement use (iron + folic acid excepted)
  • Self reported mastitis or other breast infections
  • Reported problems with breastfeeding which might affect study procedures
  • Last birth was premature (\>4 weeks pre-term by maternal report)
  • Measured body mass index (BMI) of less than 18.5 or a measured mid upper arm circumference (MUAC) of less than 12.5 cm
  • Temporary- if the mother or her infant present with an acute illness, (for example flu or diarrhea,) they will be rescheduled to return on a later date when both are apparently healthy.
  • Allergy to milk, milk products, or peanuts.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

USDA, ARS, Western Human Nutrition Research Center

Davis, California, 95616, United States

Location

Related Publications (1)

  • Donohue JA, Solomons NW, Hampel D, Shahab-Ferdows S, Orozco MN, Allen LH. Micronutrient supplementation of lactating Guatemalan women acutely increases infants' intake of riboflavin, thiamin, pyridoxal, and cobalamin, but not niacin, in a randomized crossover trial. Am J Clin Nutr. 2020 Sep 1;112(3):669-682. doi: 10.1093/ajcn/nqaa147.

MeSH Terms

Conditions

Malnutrition

Interventions

Hypoxanthine Phosphoribosyltransferase

Condition Hierarchy (Ancestors)

Nutrition DisordersNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

PentosyltransferasesGlycosyltransferasesTransferasesEnzymesEnzymes and Coenzymes

Study Officials

  • Juliana A Haber, B.S.

    USDA WHNRC, UC Davis

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
FED
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 22, 2015

First Posted

June 8, 2015

Study Start

May 1, 2015

Primary Completion

August 1, 2015

Study Completion

August 1, 2015

Last Updated

September 9, 2015

Record last verified: 2015-09

Locations